Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Biotech Industry Analysis

UpdatedApr 05, 2026
DataAggregated Company Financials
Companies21
  • 7D2.8%
  • 3M-6.5%
  • 1Y26.8%
  • YTD-6.5%

Over the last 7 days, the Biotech industry has risen 2.8%, driven by gains from Genus of 4.5%. This means that the industry has gained 27% over the past year. Looking forward, earnings are forecast to grow by 11% annually.

Industry Valuation and Performance

Has the U.K. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 05 Apr 2026UK£3.1bUK£893.2mUK£3.2m9.2x957.8x3.5x
Tue, 03 Mar 2026UK£3.5bUK£875.4m-UK£4,606,766.249.3x-753.2x4x
Thu, 29 Jan 2026UK£3.9bUK£875.9m-UK£29,180,522.2411x-132.1x4.4x
Sat, 27 Dec 2025UK£3.2bUK£896.6m-UK£29,521,075.2010.3x-108.1x3.6x
Mon, 24 Nov 2025UK£3.1bUK£895.5m-UK£30,431,642.5010.9x-102.6x3.5x
Wed, 22 Oct 2025UK£3.3bUK£878.8m-UK£44,443,239.7515.2x-73.4x3.7x
Fri, 19 Sep 2025UK£3.3bUK£857.4m-UK£83,452,510.6716.2x-40.1x3.9x
Sun, 17 Aug 2025UK£3.2bUK£854.4m-UK£103,468,659.2811.7x-30.7x3.7x
Tue, 15 Jul 2025UK£2.8bUK£854.6m-UK£103,137,662.2013.2x-26.8x3.2x
Thu, 12 Jun 2025UK£2.6bUK£857.2m-UK£104,051,695.0013.7x-24.9x3x
Sat, 10 May 2025UK£2.4bUK£879.5m-UK£95,247,877.4113.2x-25.6x2.8x
Mon, 07 Apr 2025UK£2.2bUK£845.8m-UK£277,610,134.8315.6x-7.8x2.6x
Wed, 05 Mar 2025UK£2.4bUK£844.2m-UK£279,193,004.1218.4x-8.5x2.8x
Fri, 31 Jan 2025UK£2.8bUK£842.1m-UK£295,393,786.0489.1x-9.4x3.3x
Sun, 29 Dec 2024UK£2.5bUK£841.8m-UK£294,367,694.3573.5x-8.6x3x
Tue, 26 Nov 2024UK£2.7bUK£841.2m-UK£294,948,676.7681.9x-9.1x3.2x
Thu, 24 Oct 2024UK£2.9bUK£840.3m-UK£292,176,661.9995.5x-10x3.5x
Sat, 21 Sep 2024UK£2.8bUK£831.9m-UK£310,148,019.9088.2x-8.9x3.3x
Mon, 19 Aug 2024UK£2.6bUK£837.0m-UK£251,321,657.6830.3x-10.4x3.1x
Wed, 17 Jul 2024UK£2.7bUK£837.7m-UK£256,716,061.3631.1x-10.6x3.2x
Fri, 14 Jun 2024UK£2.7bUK£835.5m-UK£272,997,425.9529.7x-9.9x3.2x
Sun, 12 May 2024UK£3.0bUK£835.9m-UK£289,863,648.0031.8x-10.2x3.5x
Tue, 09 Apr 2024UK£3.1bUK£902.3m-UK£200,807,169.0129x-15.2x3.4x
Thu, 07 Mar 2024UK£3.1bUK£897.6m-UK£203,567,954.5535x-15.2x3.4x
Sat, 03 Feb 2024UK£6.4bUK£1.3b-UK£245,773,262.0037.4x-25.9x5x
Mon, 01 Jan 2024UK£6.4bUK£1.3b-UK£245,109,120.0038.8x-26.1x5x
Wed, 29 Nov 2023UK£6.2bUK£1.3b-UK£245,430,129.0035.7x-25.2x4.9x
Fri, 27 Oct 2023UK£6.3bUK£1.3b-UK£251,430,401.0036.9x-25.2x5x
Sun, 24 Sep 2023UK£6.6bUK£1.3b-UK£223,352,067.0023.6x-29.6x5.2x
Tue, 22 Aug 2023UK£6.6bUK£1.3b-UK£207,849,496.0023.6x-31.8x5.3x
Thu, 20 Jul 2023UK£6.9bUK£1.3b-UK£208,258,685.0023.9x-33.1x5.5x
Sat, 17 Jun 2023UK£7.0bUK£1.3b-UK£204,929,275.0023.1x-34.1x5.6x
Mon, 15 May 2023UK£7.0bUK£1.3b-UK£206,820,119.0023.8x-33.6x5.5x
Wed, 12 Apr 2023UK£7.2bUK£1.2b-UK£154,095,595.0024x-47x5.8x
Price to Earnings Ratio

-47x


Total Market Cap: UK£7.2bTotal Earnings: -UK£154,095,595.00Total Revenue: UK£1.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Biotech Industry Price to Earnings3Y Average -44.2x202420252026
Current Industry PE
  • Investors are optimistic on the British Biotechs industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 958x which is higher than its 3-year average PE of -44.2x.
  • The 3-year average PS ratio of 3.9x is higher than the industry's current PS ratio of 3.5x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have gone up over the last three years and the industry is now profitable.
  • Revenues have declined 10% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, profits have been increasing.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market4.54%
Healthcare5.69%
Biotech2.80%
Biotech2.80%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GNS GenusUK£25.404.5%
+UK£73.6m		45.0%PE35.8x
BVXP BioventixUK£16.0016.4%
+UK£11.8m		-31.9%PE11.2x
PRTC PureTech HealthUK£1.132.7%
+UK£7.7m		-12.5%PE7.2x
FARN Faron Pharmaceuticals OyUK£0.4810.3%
+UK£5.2m		-77.7%PE-2.3x
BSFA BSF EnterpriseUK£0.021142.9%
+UK£1.6m		54.5%PS51.6x

Latest News

OXB
UK£5.60
Oxford Biomedica
7D
-0.2%
1Y
112.5%

OXB: Post Transition Buy Ratings Will Support Higher Quality Business Perception

Analysts have increased the updated fair value estimate for Oxford Biomedica from £9.50 to £11.70 per share, citing recent Buy ratings and higher price targets that reflect expectations for a higher quality business following the company’s transition. Analyst Commentary Recent research indicates that bullish analysts are becoming more constructive on Oxford Biomedica, with fresh Buy ratings and higher price objectives supporting the updated fair value estimate.
GNS
UK£25.40
Genus
7D
4.5%
1Y
45.0%

GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside

Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.
BSFA
UK£0.021
BSF Enterprise
7D
142.9%
1Y
54.5%
PRTC
UK£1.13
PureTech Health
7D
2.7%
1Y
-12.5%
VRCI
UK£0.0047
Verici Dx
7D
-9.5%
1Y
-85.4%
BVXP
UK£16.00
Bioventix
7D
16.4%
1Y
-31.9%
AVCT
UK£0.64
Avacta Group
7D
-2.6%
1Y
92.4%
PBX
UK£0.08
ProBiotix Health
7D
14.3%
1Y
-5.9%
AREC
UK£0.66
Arecor Therapeutics
7D
-3.6%
1Y
73.7%
4BB
UK£4.84
4basebio
7D
-5.1%
1Y
-59.0%
SVNS
UK£0.0026
Solvonis Therapeutics
7D
4.0%
1Y
52.9%
FARN
UK£0.48
Faron Pharmaceuticals Oy
7D
10.3%
1Y
-77.7%
GENF
UK£0.019
Genflow Biosciences
7D
11.4%
1Y
90.2%
SCLP
UK£0.11
Scancell Holdings
7D
-2.2%
1Y
38.0%
HEMO
UK£9.50
Hemogenyx Pharmaceuticals
7D
-2.9%
1Y
415.6%
0KF3
US$18.98
Palatin Technologies
7D
-7.4%
1Y
-27.9%